GLP-1 drug linked to heart benefits for high-risk patients
A study published in The BMJ suggests that adding the drug tirzepatide to standard care for patients with type 2 diabetes and heart disease reduces the risk of major cardiovascular events. Researchers compared outcomes against sitagliptin to determine the drug's efficacy in high-risk patients.
Why it matters
This research provides critical clinical evidence for doctors and regulators regarding the cardiovascular benefits of GLP-1 receptor agonists in managing chronic disease.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Image generated by the editorial team using AI for illustrative purposes. Adding the GLP-1 receptor agonist drug tirzepatide (marketed as Mounjaro) to standard care for patients with type 2 diabetes and heart disease is associated with a lower risk of a major cardiovascular event, such as a heart attack or stroke, finds a study published by The BMJ today.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in